LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News EARNINGS FLASH H impact Sep 29, 2026, 10:26 PM UTC

Liontown: FY27 Capex Guidance Was A$320 Million-A$370 Million Previously

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

LTR

Related stories

AI-Media Technologies Targets 22-28% Recurring Revenue Growth for FY27 AI-Media Technologies ASX:AIM is targeting year-end annual recurring revenue (ARR) of between $44 million and $46m in the 2027 financial year, representing growth of about 22% to 2 L impact | EARNINGS | Sep 29, 2026, 11:38 PM UTC Vitality Products net loss widens to $46,331 in Q2 as sales rise 54% For the three months ended July 31, 2026, Vitality Products posted a net loss of $46,331, up from $27,587, while sales rose 54% to $304,773. M impact | EARNINGS | Sep 29, 2026, 11:00 PM UTC Robinhood to Provide Easier Access to AI Agents. Plus, Weekend Trading Is Coming. — Barrons.com By Andrew WelschRobinhood Markets revealed a set of new investing tools and products for customers, including a more user-friendly way to use artificial intelligence to invest, ext H impact | EARNINGS | Sep 29, 2026, 11:00 PM UTC GenSight Biologics (SIGHT.PA) H1 2026 net loss widens to €10.3 mln, going-concern warning GenSight Biologics said its H1 2026 net loss widened to €10.3 mln versus a steady loss per share of €0.05 and warned of material uncertainty over going concern without additional f M impact | EARNINGS | Sep 29, 2026, 10:50 PM UTC Vanda Pharmaceuticals announces positive Phase III results for Hetlioz in delayed sleep-wake phase disorder Vanda said its Phase III study met the primary endpoint with a 37.1-minute sleep onset shift versus placebo, with no new safety signals identified. M impact | EARNINGS | Sep 29, 2026, 10:50 PM UTC France's GenSight Biologics H1 net loss widens on higher R&D expenses OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@l L impact | EARNINGS | Sep 29, 2026, 10:48 PM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.